Search Results

You are looking at 1 - 10 of 37 items for :

  • "endometrial carcinoma" x
Clear All
Full access

Rajmohan Murali, Deborah F. Delair, Sarah M. Bean, Nadeem R. Abu-Rustum and Robert A. Soslow

that genomic classes of endometrial carcinoma are associated with phenotypes. Copy-number-high tumors, which are characterized by TP53 mutations and alterations associated with cell cycle deregulation, constitute some high-grade endometrioid

Full access

Wui-Jin Koh, Nadeem R. Abu-Rustum, Sarah Bean, Kristin Bradley, Susana M. Campos, Kathleen R. Cho, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Shari Damast, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Suzanne George, Ernest Han, Susan Higgins, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Todd Tillmanns, Stefanie Ueda, Emily Wyse, Catheryn M. Yashar, Nicole R. McMillian and Jillian L. Scavone

this issue of JNCCN discuss important general principles and evidence for diagnosis, staging, and primary/adjuvant treatment of early-stage endometrial carcinoma. Please refer to the complete guidelines online at NCCN.org for recommendations for

Full access

Benjamin E. Greer, Wui-Jin Koh, Nadeem Abu-Rustum, Michael A. Bookman, Robert E. Bristow, Susana M. Campos, Kathleen R. Cho, Larry Copeland, Marta Ann Crispens, Patricia J. Eifel, Warner K. Huh, Wainwright Jaggernauth, Daniel S. Kapp, John J. Kavanagh, John R. Lurain III, Mark Morgan, Robert J. Morgan Jr, C. Bethan Powell, Steven W. Remmenga, R. Kevin Reynolds, Angeles Alvarez Secord, William Small Jr and Nelson Teng

corpus cancer and their potential impact on the increasing number of deaths . Am J Obstet Gynecol 2008 ; 198 : 218.e1 – 6 . 4 Duk JM Aalders JG Fleuren GJ . CA 125: a useful marker in endometrial carcinoma . Am J Obstet Gynecol 1986

Full access

Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, Kathleen R. Cho, Christina Chu, David Cohn, Marta Ann Crispens, Don S. Dizon, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Suzanne George, Ernest Han, Susan Higgins, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Todd Tillmanns, Fidel A. Valea, Catheryn M. Yashar, Nicole R. McMillian and Jillian L. Scavone

The NCCN Guidelines for Uterine Neoplasms provide interdisciplinary recommendations for treating endometrial carcinoma and uterine sarcomas. These NCCN Guidelines Insights summarize the NCCN Uterine Neoplasms Panel's 2016 discussions and major guideline updates for treating uterine sarcomas. During this most recent update, the panel updated the mesenchymal tumor classification to correspond with recent updates to the WHO tumor classification system. Additionally, the panel revised its systemic therapy recommendations to reflect new data and collective clinical experience. These NCCN Guidelines Insights elaborate on the rationale behind these recent changes.

Full access

David Scott Miller, Gini Fleming and Marcus E. Randall

References 1 Randall ME Filiaci VL Muss H . Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study . J Clin Oncol

Full access

Lauren E. Kernochan and Rochelle L. Garcia

Edited by Kerrin G. Robinson

. References 1 Vaidya AP Horowitz NS Oliva E . Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma . Gynecol Oncol 2006 ; 103 : 684 – 687 . 2 Wada H Enomoto T Fujita M . Molecular evidence

Full access

Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, John Chan, Kathleen R. Cho, David Cohn, Marta Ann Crispens, Nefertiti DuPont, Patricia J. Eifel, Amanda Nickles Fader, Christine M. Fisher, David K. Gaffney, Suzanne George, Ernest Han, Warner K. Huh, John R. Lurain III, Lainie Martin, David Mutch, Steven W. Remmenga, R. Kevin Reynolds, William Small Jr, Nelson Teng, Todd Tillmanns, Fidel A. Valea, Nicole McMillian and Miranda Hughes

recommended that gynecologic oncologists be involved in the primary management of patients with endometrial cancer. Diagnosis and Workup Approximately 90% of patients with endometrial carcinoma have abnormal vaginal bleeding, most commonly in the

Full access

Meaghan Tenney and Joan L. Walker

lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial . J Natl Cancer Inst 2008 ; 100 : 1707 – 1716 . 9 ASTEC Study Group Writing Committee . Efficacy of systematic pelvic lymphadenectomy in

Full access

Rebecca Arend, Brandon M. Roane, Selene Mesa-Perez, Whitney N. Goldsberry, Ashwini Katre, Michael J. Birrer and Lisa A. Norian

Background: Increased transforming growth factor beta (TGF-β) is associated with poorer prognosis in advanced stage endometrial carcinoma (EOC). The immunosuppressive effects of this family of proteins promotes tumor progression and diminishes

Full access

Srinivas K. Tantravahi, and Theresa L. Werner

early-stage endometrial carcinoma and locoregional recurrences. Discussion Endometrial cancer is the most common malignancy of the female genital tract in the United States, with an estimated 46,470 new cases in 2011, ranking fourth in cancer